Keytru­da hits one pri­ma­ry end­point for use be­fore and af­ter surgery in lung can­cer

Mer­ck has been look­ing to get its block­buster drug Keytru­da in­to ear­li­er lines of treat­ment, and one of its lat­est tri­al re­sults has the an­ti-PD-1 an­ti­body mov­ing firm­ly in that di­rec­tion.

Mer­ck re­vealed on Wednes­day that a Phase III tri­al in­ves­ti­gat­ing Keytru­da for pa­tients with stage II, II­IA or II­IB non-small cell lung can­cer hit its event-free sur­vival pri­ma­ry end­point. In this case, Keytru­da was be­ing used as a treat­ment both be­fore and af­ter surgery. Mea­sure­ment of over­all sur­vival, the oth­er pri­ma­ry end­point, re­mains on­go­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER